uniQure has made progress in advancing its gene therapy candidates, including AMT-130 for Huntington's disease; additional data from phase I/II study expected Q4 of 2023. Interim data from the phase I ...
uniQure N.V. (QURE) just recently reported results from its phase 1/2 study using AMT-130 for the treatment of patients with Huntington's Disease [HD]. This was interim 24-month data that showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback